Literature DB >> 29682466

Video-assisted thoracoscopic PlasmaJet ablation for malignant pleural mesothelioma.

Periklis Perikleous1, Nizar Asadi1, Vladimir Anikin1.   

Abstract

The role of surgery in malignant pleural mesothelioma (MPM) remains debatable; nonetheless the relative advantages of different surgical approaches are frequently reassessed and reconsidered. While extensive operations and longer recovery periods can be justified for a group of carefully selected patients, many will present at an advanced stage of their disease or with associated co-morbidities which will exclude them from selection criteria for radical treatment. For these patients, minimally invasive video-assisted procedures may be considered, for purposes of cytoreduction and/or symptomatic relief. Even though there is currently not enough clinical evidence to suggest an improvement in overall survival with limited debulking procedures, it has been suggested that they can improve quality of life over drainage and pleurodesis alone. We consider video-assisted PlasmaJet ablation to potentially have a role in mesothelioma surgery, as it may be used for effective cytoreduction while minimising the risk for complications often associated with extensive pleurectomy procedures, and we report on the use of the PlasmaJet Surgical System in our centre for surgical management of a patient with MPM. After demonstrating safety and absence of major adverse events with this approach, we feel justified in offering the procedure to more of our patients as we aim to collect additional data.

Entities:  

Keywords:  Mesothelioma; PlasmaJet; decortication; pleurectomy; pleurodesis; video-assisted thoracic surgery (VATS)

Year:  2018        PMID: 29682466      PMCID: PMC5897662          DOI: 10.21037/jovs.2018.02.07

Source DB:  PubMed          Journal:  J Vis Surg        ISSN: 2221-2965


  9 in total

1.  A randomized controlled trial comparing fibrin glue and PlasmaJet on the raw surface of the liver after hepatic resection.

Authors:  Jean Gugenheim; Luis César Bredt; Antonio Iannelli
Journal:  Hepatogastroenterology       Date:  2011 May-Jun

2.  Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control.

Authors:  A E Martin-Ucar; J G Edwards; A Rengajaran; S Muller; D A Waller
Journal:  Eur J Cardiothorac Surg       Date:  2001-12       Impact factor: 4.191

3.  Pathologic analysis of ex vivo plasma energy tumor destruction in patients with ovarian or peritoneal cancer.

Authors:  Yukio Sonoda; Narciso Olvera; Dennis S Chi; Carol L Brown; Nadeem R Abu-Rustum; Douglas A Levine
Journal:  Int J Gynecol Cancer       Date:  2010-11       Impact factor: 3.437

Review 4.  Randomized controlled trials in malignant pleural mesothelioma surgery-mistakes made and lessons learned.

Authors:  David A Waller; Alan G Dawson
Journal:  Ann Transl Med       Date:  2017-06

5.  Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma.

Authors:  J C Halstead; E Lim; R M Venkateswaran; S C Charman; M Goddard; A J Ritchie
Journal:  Eur J Surg Oncol       Date:  2005-04       Impact factor: 4.424

6.  Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion.

Authors:  D A Waller; G N Morritt; J Forty
Journal:  Chest       Date:  1995-05       Impact factor: 9.410

Review 7.  Video assisted thoracoscopic and open chest surgery in diagnosis and treatment of malignant pleural diseases.

Authors:  Periklis Perikleous; David A Waller
Journal:  J Vis Surg       Date:  2017-06-22

8.  Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy.

Authors:  Apostolos Nakas; Delphine Sophie Trousse; Antonio E Martin-Ucar; David A Waller
Journal:  Eur J Cardiothorac Surg       Date:  2008-07-24       Impact factor: 4.191

9.  Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial.

Authors:  Robert C Rintoul; Andrew J Ritchie; John G Edwards; David A Waller; Aman S Coonar; Maxine Bennett; Eleonora Lovato; Victoria Hughes; Julia A Fox-Rushby; Linda D Sharples
Journal:  Lancet       Date:  2014-06-16       Impact factor: 79.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.